| |
Significant improvement
|
2019
|
58.97%
|
| |
Small improvement
|
1229
|
35.89%
|
|
Treatment effect
|
No improvement
|
147
|
4.29%
|
| |
Small deterioration
|
17
|
0.50%
|
| |
Significant deterioration
|
12
|
0.35%
|
| |
Total
|
3424
|
100.00%
|
| |
Not serious
|
975
|
28.48%
|
|
Severity of disease
|
General
|
1770
|
51.69%
|
| |
Serious
|
531
|
15.51%
|
| |
Unknown
|
148
|
4.32%
|
| |
Total
|
3424
|
100.00%
|
| |
Emergency and serious disease
|
539
|
15.74%
|
|
Stage of the disease
|
Non-emergency disease at initial stage
|
2026
|
59.17%
|
| |
Non-emergency disease at medium stage
|
526
|
15.36%
|
| |
Non-emergency stable disease at late stage
|
333
|
9.73%
|
| |
Total
|
3424
|
100.00%
|
| |
[0,108)
|
856
|
25.00%
|
|
Medical expense (¥)
|
[108,258)
|
856
|
25.00%
|
| |
[258,800)
|
856
|
25.00%
|
| |
[800-
|
856
|
25.00%
|
| |
Total
|
3424
|
100.00%
|
| |
100%
|
238
|
6.95%
|
| |
(70%, 100%)
|
591
|
17.26%
|
|
Reimbursement percentage of medical costs
|
[40%, 70%)
|
500
|
14.60%
|
| |
[20%, 40%)
|
201
|
5.87%
|
| |
(0%, 20%)
|
106
|
3.10%
|
| |
0%
|
1788
|
52.22%
|
| |
Total
|
3424
|
100.00%
|
